Annual Drug Patent Expirations for BIKTARVY
Biktarvy is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from two suppliers. There are thirteen patents protecting this drug.
Drug patent litigation for BIKTARVY.
This drug has four hundred and seventy patent family members in sixty-four countries.
The generic ingredient in BIKTARVY is bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate. Two suppliers are listed for this compound. Additional details are available on the bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
